ABSTRACT
Despite extraordinary international efforts to dampen the spread and understand the mechanisms behind SARS-CoV-2 infections, accessible predictive biomarkers directly applicable in the clinic are yet to be discovered. Recent studies have revealed that diverse types of assays bear limited predictive power for COVID-19 outcomes. Here, we harness the predictive power of chest CT in combination with plasma cytokines using a machine learning approach for predicting death during hospitalization and maximum severity degree in COVID-19 patients. Patients (n=152) from the Mount Sinai Health System in New York with plasma cytokine assessment and a chest CT within 5 days from admission were included. Demographics, clinical, and laboratory variables, including plasma cytokines (IL-6, IL-8, and TNF-α) were collected from the electronic medical record. We found that chest CT combined with plasma cytokines were good predictors of death (AUC 0.78) and maximum severity (AUC 0.82), whereas CT quantitative was better at predicting severity (AUC 0.81 vs 0.70) while cytokine measurements better predicted death (AUC 0.70 vs 0.66). Finally, we provide a simple scoring system using plasma IL-6, IL-8, TNF-α, GGO to aerated lung ratio and age as novel metrics that may be used to monitor patients upon hospitalization and help physicians make critical decisions and considerations for patients at high risk of death for COVID-19.
Competing Interest Statement
S.G. reports consultancy and/or advisory roles for Merck and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Celgene, Janssen R&D, Takeda, and Regeneron.
B.T. reports consultancy and/or advisory roles for Bayer, Helio Health and research funding/support from Bayer, Takeda, Regeneron, Echosens.
Funding Statement
Authors wish to acknowledge Rajiv Pande and Martin Putnam at Bio-techne for helping to provide instruments and assay kits for ELLA testing in a CLIA environment in the timeliest possible way during the health crisis. Additionally, this work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.
S.G., E.G.K, D.M.D.V. and M.M were supported by NCI U24 grant CA224319. S.G. and D.M.D.V. is additionally supported by grant U01 DK124165.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by The Human Research Protection Program at the Icahn School of Medicine at Mount Sinai (HS # 20-00429). A waiver of consent was obtained to query the electronic medical record.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DATA AVAILABILITY STATEMENT The data supporting this publication has been made available at ImmPort (https://www.immport.org) under study accession number SDY1752. The dataset has been de-identified in compliance with United States Federal Health Insurance Portability and Accountability Act (HIPAA). ImmPort is a data sharing and analysis portal for immunology research community funded by the National Institute of Allergy and Infectious Diseases (NIAID), Division of Allergy, Immunology, and Transplantation (DAIT). Please refer to the ImmPort user agreement for further details (https://www.immport.org/agreement).
CODE AVAILABILITY STATEMENT Scripts used to query the Clarity and Caboodle databases, as well as the statistical analysis, have been uploaded to GitHub repository, https://github.com/eegk/covid19_radiology.
COMPETING INTERESTS S.G. reports consultancy and/or advisory roles for Merck and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Celgene, Janssen R&D, Takeda, and Regeneron. B.T. reports consultancy and/or advisory roles for Bayer, Helio Health and research funding/support from Bayer, Takeda, Regeneron, Echosens.
All authors reviewed and approved final manuscript.
Data Availability
The data supporting this publication has been made available at ImmPort (https://www.immport.org) under study accession number SDY1752. The dataset has been de-identified in compliance with United States Federal Health Insurance Portability and Accountability Act (HIPAA). ImmPort is a data sharing and analysis portal for immunology research community funded by the National Institute of Allergy and Infectious Diseases (NIAID), Division of Allergy, Immunology, and Transplantation (DAIT). Please refer to the ImmPort user agreement for further details (https://www.immport.org/agreement).
ABBREVIATIONS
- AUC
- Area Under the Curve
- COVID-19
- Novel coronavirus discovered in 2021 Wuhan
- CT
- Computed Tomography
- EMR
- Electronic Medical records
- GGO
- Ground-Glass Opacities
- HU
- Hounsfield Units
- IL-6
- Interleukin 6
- IL-8
- Interleukin 8
- IQR
- Inter Quartile Range
- ROC
- Receiver Operating Characteristic
- TNF-α
- Tumor Necrosis Factor alpha
- WHO
- World Health Organization
